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Introduction {#sec005}
============

Inflammatory bowel diseases (IBDs) are a group of chronic and non-specific intestinal inflammatory disorders including ulcerative colitis (UC) and Crohn's disease (CD). Although the precise etiology of IBDs is not yet fully understood, abnormal host-microbial interactions have been implicated in the pathogenesis of IBD. Mucosal and fecal bacterial analyses have suggested that patients with IBD have less complex commensal bacteria population and higher numbers of mucosal-associated bacteria than healthy individuals \[[@pone.0146557.ref001]--[@pone.0146557.ref003]\]. Animal models have also indicated that the composition of intestinal microbiota influenced intestinal inflammation \[[@pone.0146557.ref004]\]. The composition of intestinal microbiota appears to be influenced by host genetics. For instance, in patients with IBD carrying the *NOD2* and *ATG16L1* risk alleles the intestinal microbiota contains lower levels of *Faecalibacterium* and higher levels of *Escherichia* \[[@pone.0146557.ref005]\].

The intestinal microbiota can be influenced by Fucosyltransferase (*FUT*) *2* and *FUT3*, which control presentation of histo-blood group antigens (HBGA) on the gastrointestinal mucosa and in bodily secretions. HBGA, including ABH antigens and Lewis antigens, act not only as binding sites for intestinal microbes such as *Helicobacter pylori*, *Campylobacter jejuni*, *Norovirus* and *rotavirus* \[[@pone.0146557.ref006]--[@pone.0146557.ref008]\], but also a carbon source for microbes including *Escherichia coli* \[[@pone.0146557.ref009]\]. *FUT2* is located in chromosome 19q13, while *FUT3* is mapped to chromosome 19p13, a genomic region containing putative susceptibility loci (IBD6) for IBD \[[@pone.0146557.ref010],[@pone.0146557.ref011]\]. *FUT2* influences presentation of ABH antigens in the gastrointestinal mucosa and their secretion. In people that express functional *FUT2*, termed secretors, expression of ABH antigens is widespread in the stomach and small intestine, but decreases progressively from the proximal to distal colon \[[@pone.0146557.ref012],[@pone.0146557.ref013]\]. Homozygotes for loss-of-function alleles in *FUT2* lack expression of ABH antigens in the gastrointestinal mucosa and bodily secretions and account for approximately 20% of the world's population \[[@pone.0146557.ref014]--[@pone.0146557.ref016]\]. *FUT2*(rs601338, G428A) is the most common polymorphism in *FUT2* Caucasian nonsecretors. In Chinese and Japanese populations, however, *FUT2* (rs601338, G428A) is rare and instead the more common missense mutation *FUT2* (rs1047781, A385T) is responsible for dramatically decreased expression of ABH antigens \[[@pone.0146557.ref015]--[@pone.0146557.ref017]\]. Additionally, *FUT2* (rs281377, T357C) has been identified as a common silent mutation in Chinese non-secretors \[[@pone.0146557.ref018], [@pone.0146557.ref019]\].

*FUT3* encodes α-(1,3/4)-fucosyltransferase required to synthesize Lewis a antigens, and mostly utilizes the H antigen, determined by FUT2, as a substrate to synthesize Lewis b antigen. Lewis b is mainly expressed in the proximal colon, but not expressed in the distal colon, whereas Lewis a is uniformly distributed throughout the colon \[[@pone.0146557.ref013]\]. Studies in Chinese populations have demonstrated that (rs28362459, T59G), (rs3745635, G508A) and (rs3894326, T1067A) were the most common polymorphic loci of *FUT3* \[[@pone.0146557.ref018]\]. Furthermore, mutations of *FUT3* (rs3745635) and (rs3894326) inactivate the enzyme \[[@pone.0146557.ref010], [@pone.0146557.ref020]\], while mutation of *FUT3* (rs28362459) reduces the availability of α-(1,3/4)-fucosyltransferase \[[@pone.0146557.ref010], [@pone.0146557.ref019]\].

In recent years, several studies have linked several nucleotide polymorphisms in *FUT2* to intestinal microbiota composition \[[@pone.0146557.ref021]\] and predisposition to CD \[[@pone.0146557.ref022], [@pone.0146557.ref023]\], celiac disease \[[@pone.0146557.ref024]\], type 1 diabetes \[[@pone.0146557.ref025]\] and primary sclerosing cholangitis \[[@pone.0146557.ref026]\], highlighting the essential role of host gene-microbiota interaction in autoimmune diseases. However, the conclusions drawn about the influence of *FUT2* on UC, were not consistent. Additionally, few studies have investigated the influence of *FUT3* polymorphisms on UC. In this study, we investigated the prevalence of *FUT2* and *FUT3* polymorphisms in a cohort of UC patients and healthy controls in Southeast China. We also evaluated intestinal expression of Lewis a and b antigens to further investigate the role of these genes in pathogenesis of UC.

Materials and Methods {#sec006}
=====================

Subjects {#sec007}
--------

Between January 2004 and May 2015, 485 consecutive UC patients were recruited from The Second Affiliated Hospital of Wenzhou Medical University in Wenzhou city, Zhejiang province of Southeast China. UC was diagnosed according to colonoscopic, histo-pathological, radiologic and clinical findings, following the Lennard-Jones Criteria \[[@pone.0146557.ref027]\]. The severity of UC were evaluated by Truelove & Witt Activity Index \[[@pone.0146557.ref028]\]. In the corresponding period, a total of 580 age- and sex-matched healthy controls were enrolled at the Health Examination Center of The Second Affiliated Hospital of Wenzhou Medical University. Patients with autoimmune diseases, tumors, and IBD family history were excluded. Demographic data was collected ([Table 1](#pone.0146557.t001){ref-type="table"}). The age and sex distribution did not differ significantly between these UC patients and controls. Of these UC patients, we obtained specimens of inflammatory lesions in the sigmoid colon during colonoscopy examination. Specimens of the adjacent non-inflammatory mucosa were also obtained in five of the 7 patients. In seven patients with benign colonic polyps, confirmed by colonoscopy examination and pathology, specimens of normal sigmoid colon mucosa were obtained during colonoscopy. The study was carried out in line with the Treaty of Helsinki and was approved by Ethics Committee of The Second Affiliated Hospital of Wenzhou Medical University. Written informed consent was obtained from all UC patients and controls.

10.1371/journal.pone.0146557.t001

###### Demographic characteristics of UC patients and the controls.

![](pone.0146557.t001){#pone.0146557.t001g}

  Characteristics                      UC             Controls       *P*
  ------------------------------------ -------------- -------------- -------
  Total number                         485            580            
  Sex (Female/Male)                    201/284        261/319        0.243
  Age (years) \[mean (SD)\]            40.23(15.32)   41.09(17.11)   0.392
  Age of onset (years) \[mean (SD)\]   39.05(14.47)                  
  Smoking \[n (%)\]                                                  0.124
  Current or ex-smoker                 80(16.5)       117(20.2)      
  Never smoked                         405(83.5)      463(79.8)      
  Lesion location \[n (%)\]                                          
  Distal colitis                       311(64.1)                     
  Extensive colitis                    174(35.9)                     
  Severity of UC \[n (%)\]                                           
  Mild                                 188(38.8)                     
  Intermediate                         223(46.0)                     
  Severe                               74(15.3)                      
  Treatment \[n (%)\]                                                
  SASP/5-ASA                           408(84.1)                     
  Prednisone                           118(24.3)                     
  Antibiotics                          170(35.1)                     
  Immunosuppressant                    9(1.9)                        
  Infliximab                           0(0)                          
  Colectomy                            2(0.4)                        

UC, ulcerative colitis. SD, standard deviation. SASP, sulfasalazine. 5-ASA, 5-aminosalicylic acid.

Genomic DNA Extraction and Genotyping {#sec008}
-------------------------------------

Approximately 5 ml of peripheral blood was collected from each study subject in an EDTA tube. Genomic DNA was extracted from peripheral blood using the DNeasy Blood & Tissue kit (Qiagen GmbH), according to the manufacturer's instructions. Genomic DNA was stored at 4°C for subsequent identification of genetic mutations.

We employed a Multiplex *SNaPshot* assay (Applied Biosystems, California, USA) to examine *FUT2* and *FUT3* genotypes. First, 10 ng of genomic DNA was added to a 10 μl PCR mixture containing 20 μmol dNTPs (Promega, Wisconsin, USA), 0.5 U FastStart Taq DNA polymerase (Roche, Basel, Switzerland), 1μl 10×PCR buffer with MgCl~2~ (15 mmol/L) (Roche, Basel, Switzerland) and amplification primers with a specific final concentration ([Table 2](#pone.0146557.t002){ref-type="table"}). The thermal cycler conditions for multiplex PCR amplification were as follows: initial denaturation, 95°C for 5 min, amplification for 35 cycles at 94°C for 30 s, 65°C for 30 s and 72°C for 1 min, followed by a final elongation step at 72°C for 10 min. Subsequently, the PCR products were examined by electrophoresis on a 2.5% agarose gel. Second, we purified the PCR product using a mix of 1.5 U shrimp alkaline phosphatase (SAP) (New England Biolabs, Massachusetts, USA) and 2 U Exonuclease I (TAKARA, Dalian, China) at 37°C for 80 min, then 85°C for 15 min. Third, the multiplex SNaPshot sequencing reactions were carried out in a final volume of 7 μl containing 2 μl of purified multiple PCR products, 1 μl SNaPshot Multiplex Mix, 1 μl 5×Sequencing buffer (Applied Biosystems) and 3 μl *SNaPshot* sequencing primers (the final concentrations are listed in [Table 2](#pone.0146557.t002){ref-type="table"}). The thermal cycler conditions were: initial denaturation at 96°C for 1 min followed by 25 cycles at 96°C for 10 s, 52°C for 5 s and 60°C for 30 s. Then depuration of product was performed with 1 U SAP at 37°C for 60 min and 75°C for 15 min. Finally, 1.5 μl of *SNaPshot* products were genotyped using the ABI 3730 Genetic Analyzer before they were mixed with 8 μl HiDi^TM^ formamide and 0.5 μl GeneScan-120LIZ size standard (Applied Biosystems). Data were analyzed using GeneMapper 4.0 (Applied Biosystems). In order to guarantee quality of the study, about 3 percent of the samples were randomly selected and re-genotyped by direct sequencing. The regenotyping and *SNaPshot* results were in complete accordance with original results.

10.1371/journal.pone.0146557.t002

###### Amplification and extension primers of *FUT2* and *FUT3*.

![](pone.0146557.t002){#pone.0146557.t002g}

  SNP                 Amplification Primer (5′→3′)                            Size (bp)   Conc.(μM)   Extension primer (5′→3′)          Size (bp)   Conc. (μM)
  ------------------- ------------------------------------------------------- ----------- ----------- --------------------------------- ----------- ------------
  *FUT2* rs281377     F:TCAACATCAAAGGCACTGGGACC R:TGGCGGAGGTGGTGGTAGAA        338         2.5         **18T**-TGGCAGAACTACCACCTGAA      38          1
  *FUT2* rs1047781    F:TCAACATCAAAGGCACTGGGACC R:TGGCGGAGGTGGTGGTAGAA        338         2.5         **38T**-TGGAGGAGGAATACCGCCAC      58          1
  *FUT2* rs601338     F:TCAACATCAAAGGCACTGGGACC R:TGGCGGAGGTGGTGGTAGAA        338         2.5         CACCGGCTACCCCTGCTCCT              20          1
  *FUT3* rs28362459   F:AAGAAACACACAGCCACCAGCAG R:AATGACCCTCACTCCTCTCTCCTCT   137         1           **31T**-GCGCCGCTGTCTGGCCGCAC      51          1
  *FUT3* rs3745635    F:GGCTGAGTCCGGCTTCCAGTT R:TATCATGTCCAACCCTAAGTCACGC     280         1           **5T**-CCGACATCTTCACGCCCTAC       25          1
  *FUT3* rs3894326    F:AGGTCCCTAGCAGGCAAGTCTTC R:CTGGGCACTGGATTTCTGCAAGG     254         1           **21T**-CAGGTACCAGACGGTGCGCAGCA   44          1

Bold characters refer to the 5' poly-thymidine tail.

Immunohistochemistry {#sec009}
--------------------

For immunohistochemical analysis, formalin-fixed paraffin-embedded tissue sections were de-paraffinized with xylene and rehydrated with ethanol solutions and distilled water. Antigen retrieval was performed by heating the sections in EDTA antigen retrieval buffer (pH 9.0) at 99°C for 25 min. Then the slides were washed in PBS (pH 7.4) three times for 5 min. After blocking in endogenous peroxidase with 3% hydrogen peroxide solution at room temperature for 25 min, the slides were again washed in PBS (pH 7.4) three times for 5 min. To block unspecific antibody binding, sections were incubated with 3% BSA (Solarbio, Beijing, China) for 30 min. Sections were then incubated overnight at 4°C in PBS (pH 7.4) containing primary antibodies, blood group Lewis a and b antibodies (Catalog number: sc-51512 and sc-51513, Santa Cruz Biotech, Texas, U.S.A.) at 1:20 in PBS (pH 7.4). Sections were washed three times in PBS then incubated with polyclonal goat anti-mouse immunoglobulins/HRP (Dako, Glostrup, Denmark) at room temperature for 50 min. The the slides were rinsed in PBS three times for 5 min and HRP was added. Rabbit/Mouse (DAB+). Harris staining was performed to highlight the nucleus of cells.

Lewis antigen expression was evaluated quantitatively using the Image Pro Plus 6.0 analysis system (Media Cybernetics, Silver Spring, MD) by calculating the mean density, which was integrated optical density (IOD) divided by area of interest \[[@pone.0146557.ref029]\]. Three 200X fields under microscope of each slide were randomly selected and the mean density was obtained for further statistic analysis.

Statistical Analysis {#sec010}
--------------------

Hardy-Weinberg equilibrium for genotypes was evaluated by *chi-square* test both in UC patients and the controls. Either *chi-square* or *Fisher's* exact test was applied to compare categorical variables such as alleles and genotypes. Unconditional logistic regression analysis was employed to investigate the allelic and genotypic distributions in UC patients, stratified by their clinical characteristics. Covariants included age, gender, smoking, lesion location and severity of UC. Linkage disequilibrium (LD) was estimated and visualized by *Haploview* 4.2. Haplotypes were reconstructed and haplotype frequencies were calculated by *Phase* 2.1 software \[[@pone.0146557.ref030]\]. Mann-Whitney U-test was applied to compare expression of Lewis antigens. All statistical data were input into *SPSS* 17.0 software (SPSS for Windows version 17.0, Chicago, IL, USA). A two-tailed *P* value less than 0.05 was considered significant.

Results {#sec011}
=======

Comparison of alleles and genotypes of *FUT2* and *FUT3* between UC patients and controls {#sec012}
-----------------------------------------------------------------------------------------

In this study, the genotype distributions of *FUT2* and *FUT3* were shown to be in good agreement with Hardy-Weinberg equilibrium both in UC patients and the controls (all *P*\>0.05). The allele and genotype frequencies of SNPs in *FUT2* did not differ significantly between UC patients and the controls (all *P*\>0.05). However, the frequencies of mutant allele (A) and genotype (GA+AA) in *FUT3* (rs3745635) were higher in UC patients than the controls (*P* = 0.016, 95%*CI*: 1.339--1.699; *P* = 0.038, 95%*CI*: 1.330--1.742, respectively). In addition, the most common homozygous mutation of *FUT2* (rs601338), which led to nonsecretors in Caucasians, was not observed in our study. Several healthy controls (17.3%) were homozygous for *FUT2* (rs1047781 T), thus nonsecretors ([Table 3](#pone.0146557.t003){ref-type="table"}, Dataset in [S1 Dataset](#pone.0146557.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0146557.t003

###### Allelic and genotypic distributions of *FUT2* and *FUT3* between UC patients and the controls.
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  Genotype/allele     Controls(580) n(%)   UC (485)n(%)   OR (95%CI)            *P*
  ------------------- -------------------- -------------- --------------------- -------
  *FUT2* rs281377                                                               
  TT                  441(76.0)            356(73.4)                            
  TC                  126(21.7)            114(23.5)                            
  CC                  13(2.2)              15(3.1)                              
  TC+CC               139(24.0)            129(26.6)      0.871(1.150--1.517)   0.324
  allele C            152(13.1)            144(14.8)      0.904(1.156--1.478)   0.247
  *FUT2* rs1047781                                                              
  AA                  160(27.6)            155(32.0)                            
  AT                  314(54.1)            247(50.9)                            
  TT                  106(18.3)            83(17.1)                             
  AT+TT               420(72.4)            330(68.0)      0.623(0.811--1.056)   0.119
  allele T            526(45.3)            413(42.6)      0.753(0.894--1.061)   0.200
  *FUT2* rs601338                                                               
  GG                  575(99.1)            479(98.8)                            
  GA                  5(0.9)               6(1.2)                               
  AA                  0(0)                 0(0)                                 
  GA+AA               5(0.9)               6(1.2)         0.437(1.441--4.749)   0.547
  allele A            5(0.4)               6(0.6)         0.437(1.438--4.726)   0.548
  *FUT3* rs28362459                                                             
  TT                  332(57.2)            281(57.9)                            
  TG                  219(37.8)            174(35.9)                            
  GG                  29(5.0)              30(6.2)                              
  TG+GG               248(42.8)            204(42.1)      0.761(0.972--1.241)   0.819
  allele G            277(23.9)            234(24.1)      0.830(1.013--1.237)   0.895
  *FUT3* rs3745635                                                              
  GG                  435(75.0)            336(69.3)                            
  GA                  136(23.4)            133(27.4)                            
  AA                  9(1.6)               16(3.3)                              
  GA+AA               145(25.0)            149(30.7)      1.016(1.330--1.742)   0.038
  allele A            154(13.3)            165(17.0)      1.055(1.339--1.699)   0.016
  *FUT3* rs3894326                                                              
  TT                  471(81.2)            406(83.7)                            
  TA                  105(18.1)            76(15.7)                             
  AA                  4(0.7)               3(0.6)                               
  TA+AA               109(18.8)            79(16.3)       0.611(0.841--1.156)   0.286
  allele A            113(9.7)             82(8.5)        0.635(0.856--1.153)   0.305

Haplotype analysis of *FUT2* and *FUT3* {#sec013}
---------------------------------------

Two LD blocks were presented as follows: block rs281377-rs1047781 in *FUT2* (*D*\' = 0.96, r^2^ = 0.11) and block rs3894326-rs3745635-rs28362459 in *FUT3* \[rs3894326/rs3745635 (*D\'* = 1, r^2^ = 0.01), rs3894326/rs28362459 (*D*\' = 0.86, r^2^ = 0.23), rs3745635/rs28362459 (*D\'* = 0.92, r^2^ = 0.47)\] ([Fig 1](#pone.0146557.g001){ref-type="fig"}). Furthermore, we conducted a haplotype analysis in all study subjects to investigate whether any specific haplotype would confer risk of or protection from UC. No haplotypes differed significantly between UC patients and the controls (all *P*\>0.05, [Table 4](#pone.0146557.t004){ref-type="table"}).

![Linkage disequilibrium patterns of *FUT2* and *FUT3* in Chinese Han populations.\
Numbers indicated the percentage of D\' between 2 SNPs and in the dark area which have no digital represents D\' = 1. Dark color indicated strong connection. Block 1 illustrated linkage disequilibrium in the 3 SNP in *FUT3*, and block 2 showed that rs281377 was in linkage disequilibrium with rs1047781 in *FUT2*.](pone.0146557.g001){#pone.0146557.g001}

10.1371/journal.pone.0146557.t004

###### Haplotype frequencies of *FUT2* and *FUT3* in patients with UC and the controls.

![](pone.0146557.t004){#pone.0146557.t004g}

  Groups     *FUT2* (rs281377-rs1047781)   *FUT3* (rs3894326- rs3745635-rs28362459)                           
  ---------- ----------------------------- ------------------------------------------ ------- ------- ------- -------
  UC         0.425                         0.427                                      0.148   0.733   0.158   0.071
  Controls   0.450                         0.419                                      0.127   0.752   0.129   0.093

No positive results were obtained for each haplotype of *FUT2* and *FUT3* between UC patients and the controls (all *P* \>0.05). The haplotype frequencies lower than 0.030 were not presented in the table.

Association between *FUT2* and *FUT3* polymorphisms and clinical characteristics of patients with UC {#sec014}
----------------------------------------------------------------------------------------------------

Unconditional logistic regression analysis was used to evaluate the associations between *FUT2* and *FUT3* polymorphisms and clinical characteristics of UC patients. Covariants included age, gender, smoking, lesion location and severity of UC. The frequencies of mutant allele (G) and genotype (TG+GG) of *FUT3* (rs28362459) were significantly lower in patients with extensive colitis than in those with distal colitis (*P*\<0.001, 95%*CI*: 0.503--0.742; *P* = 0.001, 95%*CI*: 0.567--0.786, respectively). The frequencies of mutant allele (A) and genotype (GA+AA) of *FUT3* (rs3745635) in patients with extensive colitis were significantly lower than in patients with distal colitis (*P* = 0.006, 95%*CI*: 0.553--0.845; *P* = 0.011, 95%*CI*: 0.621--0.900, respectively) ([Table 5](#pone.0146557.t005){ref-type="table"}). However, none of the six SNPs of *FUT2* and *FUT3* were significantly associated with UC severity in this sample (all *P*\>0.05).

10.1371/journal.pone.0146557.t005

###### Association of *FUT2* and *FUT3* polymorphisms with clinical characteristics of UC patients.
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  Genotype/Allele     Distal colitis(n = 311)(%)   Extensive colitis(n = 174)(%)   OR(95%CI)             *P*
  ------------------- ---------------------------- ------------------------------- --------------------- -------
  *FUT2* rs281377                                                                                        
  TT                  231(74.3)                    125(71.8)                                             
  TC+CC               80(25.7)                     49(28.2)                        0.746(1.132--1.717)   0.560
  T allele            532(85.5)                    294(84.5)                                             
  C allele            90(14.5)                     54(15.5)                        0.753(1.086--1.566)   0.660
  *FUT2* rs1047781                                                                                       
  AA                  90(28.9)                     65(37.4)                                              
  AT+TT               221(71.1)                    109(62.6)                       0.461(0.683--1.012)   0.057
  A allele            346(55.6)                    211(60.6)                                             
  T allele            276(44.4)                    137(39.4)                       0.623(0.814--1.063)   0.131
  *FUT2* rs601338                                                                                        
  GG                  308(99.0)                    171(98.3)                                             
  GA+AA               3(1.0)                       3(1.7)                          0.360(1.801--9.022)   0.468
  G allele            619(99.5)                    345(99.1)                                             
  A allele            3(0.5)                       3(0.9)                          0.360(1.794--8.938)   0.469
  *FUT3* rs28362459                                                                                      
  TT                  162(52.1)                    119(68.4)                                             
  TG+GG               149(47.9)                    55(31.6)                        0.340(0.503--0.742)   0.000
  T allele            450(72.3)                    286(82.2)                                             
  G allele            172(27.7)                    62(17.8)                        0.409(0.567--0.786)   0.001
  *FUT3* rs3745635                                                                                       
  GG                  202(65.0)                    134(77.0)                                             
  GA+AA               109(35.0)                    40(23.0)                        0.362(0.553--0.845)   0.006
  G allele            502(80.7)                    303(87.1)                                             
  A allele            120(19.3)                    45(12.9)                        0.429(0.621--0.900)   0.011
  *FUT3* rs3894326                                                                                       
  TT                  253(81.4)                    153(87.9)                                             
  TA+AA               58(18.6)                     21(12.1)                        0.350(0.599--1.025)   0.060
  T allele            562(90.4)                    326(93.7)                                             
  A allele            60(9.6)                      22(6.3)                         0.381(0.632--1.050)   0.074

The covariants also included sex, age of onset, smoking, severity of the disease. Nevertheless, these covariants did not affect the allelic and genotypic distributions of *FUT2* and *FUT3* in UC patients and the controls.

Expression of Lewis a and b antigens in the sigmoid colon {#sec015}
---------------------------------------------------------

We used immunohistochemical staining techniques to investigate expression of Lewis a and b antigens in the sigmoid colon of 7 UC patients and 7 patients with benign colonic polyps. Lewis a and b were expressed in the sigmoid colon of all studied samples, regardless of the *FUT2* or *FUT3* genotype ([Fig 2](#pone.0146557.g002){ref-type="fig"}, [Table 6](#pone.0146557.t006){ref-type="table"}). In the normal mucosa of patients with benign colonic polyps, Lewis a was mostly expressed in the epithelium, while expression of Lewis b was observed in the cells and extracellular matrix. Immunohistochemical staining of Lewis a indicated increased expression in the cryptic epithelium of inflammatory lesions in UC patients than the normal mucosa of patients with benign colonic polyps (*P* = 0.028), although there was no difference of Lewis a expression in surface epithelium between the two groups. Notably, the extent of Lewis a staining did not differ significantly between inflammatory lesions and adjacent non-inflammatory mucosa of UC patients. In addition, the expression of Lewis b did not differ significantly among the inflammatory lesions, adjacent non-inflammatory mucosa of UC patients and normal control mucosa.

![Representative Sigmoid Colon specimens of UC patients and patients with benign colonic polyps.\
Expression of Lewis a antigen (a-c) and Lewis b antigen (d-f) in the sigmiod specimens of inflammatory and adjacent non-inflammatory tissue of UC patients and normal controls. Samples a, b, d, e were derived from patient 5, described in [Table 6](#pone.0146557.t006){ref-type="table"}. Samples c and f were derived from normal tissue of patients with benign colonic polyps. Immunohistochemical staining indicated increased expression of Lewis a antigen in the cryptic epithelium in inflammatory lesions from UC patients and normal mucosa from patients with benign colonic polyps (see arrows in a-c). Expression in the epithelium did not differ dramatically between UC patients and patients with benign colonic polyps. Expression of Lewis b antigen did not differ dramatically between the three groups (d--f).](pone.0146557.g002){#pone.0146557.g002}

10.1371/journal.pone.0146557.t006

###### Demographic characteristics of UC patients for immunohistochemistry study.
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  Case   Sex      Age   Smo-king   Lesion location   Disease severity   FUT2 Genotype                       FUT3 Genotype
  ------ -------- ----- ---------- ----------------- ------------------ ----------------------------------- -------------------------------------
  1      Male     56    yes        Distal            Mild               FUT2 rs1047781 ATFUT2 rs281377 CT   FUT3 rs28362459 GTFUT3 rs3894326 AT
  2      Female   45    no         Distal            Severe             FUT2 rs1047781 TT                   Wild type
  3      Female   22    no         Extensive         Mild               Wild type                           FUT3 rs28362459 GT
  4      Male     42    no         Distal            Mild               Wild type                           Wild type
  5      Male     47    yes        Distal            Intermediate       Wild type                           Wild type
  6      Female   42    no         Distal            Intermediate       Wild type                           Wild type
  7      Female   51    no         Extensive         Intermediate       Wild type                           Wild type

One UC patient who carried homozygous mutation of *FUT2* (rs1047781) expressed same levels of Lewis a and b antigens. This might indicate that *FUT2* genotypes have a minimal effect on expression of Lewis a and b antigens. We also noticed that expression of Lewis a and b antigen was decreased in one UC patient carrying mutant genotypes of *FUT3* (rs28362459 GT, rs3894326 AT) and *FUT2* (1047781 AT, rs281377 CT).

Discussion {#sec016}
==========

In this study, we investigated the frequency of mutations in *FUT2* and *FUT3* in Chinese patients with UC and healthy controls. In this population we found that *FUT2* polymorphisms were not significantly associated with UC. However, the frequencies of mutant allele (A) and genotype (GA+AA) of *FUT3* (rs3745635) were higher in UC patients than in the controls. Furthermore, stratified analyses also indicated that the mutant alleles and genotypes of *FUT3* (rs28362459 and rs3745635) were more common in patients with distal colitis than those with extensive colitis. These findings suggested that mutations in *FUT3* not only are associated with UC, but also might affect the location of lesions.

To our knowledge, the role of FUT3 in UC has not previously been reported. However, recent studies have linked several mutations in *FUT3* to the risk of colon cancer \[[@pone.0146557.ref031]\], peptic ulcer, atrophic gastritis \[[@pone.0146557.ref032],[@pone.0146557.ref033]\], Norovirus infection \[[@pone.0146557.ref034]\], type 2 diabetes \[[@pone.0146557.ref035]\] and coronary heart disease \[[@pone.0146557.ref036]\]. Moreover, the products of *FUT3*, Lewis a and b antigen, are involved in host-microbial interactions \[[@pone.0146557.ref006]--[@pone.0146557.ref009]\].

Next, we used immunohistochemistry to evaluate expression of Lewis a and b antigens in the sigmoid colon of UC patients and patients with benign colonic polyps. In our study, Lewis a and b were expressed in the sigmoid colon of all studied samples, including one UC patient (case 2) who carried homozygous mutation of FUT2 rs1047781. This might indicate that the FUT2 genotypes have a minimal effect on expression of Lewis a and b antigens.

Notably, expression of Lewis a and b antigen remained unchanged in one UC patient (case 3) with mutant *FUT3* (rs28362459) genotype GT, while decreased in one UC patient (case 1) carrying mutant genotypes of *FUT3* (rs28362459 GT, rs3894326 AT) and *FUT2* (1047781 AT, rs281377 CT). These observations suggested that heterozygous mutation of rs3745635 reduced the function of α-(1,3/4)-fucosyltransferase more significantly than rs28362459. These observations may suggest a cumulative effect of *FUT3* mutations on its expression.

In comparison to healthy control samples, expression of Lewis a was higher in the cryptic epithelium in both inflammatory lesions and non-inflammatory tissue from UC patients, although no difference was found in surface epithelium between these groups. This finding suggested the potential role of Lewis a antigen in the pathogenesis of UC. Notably, the finding that expression of Lewis a antigen was also increased in non-inflammatory tissue might indicate that Lewis a antigen expression was upregulated before inflammation occurred. However, the sample size involved in the genotype-phenotype study is too small to draw any precise conclusions. Studies involving a larger number of patients and genotypes will be required to illustrate the genotype-phenotype effect of the two genes.

Lewis antigens have previously been implicated in intestinal microbiota composition \[[@pone.0146557.ref006], [@pone.0146557.ref021], [@pone.0146557.ref034]\]. The intestinal microbiota of individuals with negative Lewis blood groups were recently reported to contain a less rich and diverse range of bacteria than those with Lewis a phenotype \[[@pone.0146557.ref021]\]. In addition, fucose released from Lewis antigens was reported to play a key role in the pathogenicity and metabolism of enterohaemorrhagic *Escherichia coli* (EHEC) \[[@pone.0146557.ref009]\].

Some studies have previously explored the association between *FUT2* polymorphisms and IBD. McGovern *et al*. found that in a Caucasian population non-secretion, caused by a *FUT2* (rs601338) polymorphism, was associated with CD, but not UC. However, in a Finnish population the wild GG genotype of *FUT2* (rs601338) was associated with enhanced risk of UC \[[@pone.0146557.ref024]\]. And in a Chinese Han population mutations in *FUT2* (rs281377 and rs601338) predisposed patients to UC, while *FUT2* (rs1047781 and rs601338) polymorphisms were associated with UC in Uyghur population from northwest China \[[@pone.0146557.ref037]\]. In this study we found no association between *FUT2* polymorphisms and UC. Although our finding may indicate the absence of association between UC and *FUT2* polymorphisms in Chinese population, the conclusions are limited by the relatively small sample size analyzed in this study. Given the multifactorial nature of UC, many rare genetic variants may contribute to its development, and a wide range of rare variants, or the potential dependency of multiple variants, is not easily identified in these relatively small sample sizes.

Our results, however, suggested that mutations in *FUT3* and its intestinal expression might be associated with UC susceptibility in Chinese patients. Studies involving larger cohort of UC patients will be required to validate the role of *FUT3* in UC.
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